USPTO Patent Application: Allosteric Modulators for CRPC Therapy

ChangeBridge: Patent Apps - Pharma (A61K)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083751A1) from the University of Pittsburgh detailing allosteric modulators of the androgen receptor for treating castration-resistant prostate cancer (CRPC). The application describes small molecule compounds that may inhibit androgen receptor coactivator recruitment.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083751A1) filed by the University of Pittsburgh. It discloses small molecule allosteric modulators of the androgen receptor, designed to inhibit coactivator recruitment and potentially treat castration-resistant prostate cancer (CRPC). The application details the chemical compounds and a method of treatment.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in CRPC therapeutics, which may be of interest to pharmaceutical companies and researchers in the oncology space. No immediate actions are required for compliance officers.

Source document (simplified)

← USPTO Patent Applications

ALLOSTERIC MODULATORS OF ANDROGEN RECEPTOR COACTIVATOR RECRUITMENT FOR CRPC THERAPY

Application US20260083751A1 Kind: A1 Mar 26, 2026

Assignee

University of Pittsburgh – Of the Commonwealth System of Higher Education

Inventors

Paul A. Johnston, Andrew P. Hinck, Carlos J. Camacho, Peter Wipf, Zhou Wang, Lee A. McDermott

Abstract

Small molecule allosteric modulators of androgen receptor are disclosed. The compounds may inhibit androgen receptor coactivator recruitment, such as by preventing formation of protein-protein interaction (PPI) complexes and/or disrupting PPI complexes. A method of treating prostate cancer, such as castration-resistant prostate cancer, includes administering a small molecule allosteric modulator of androgen receptor.